ST
NVCR icon

Spot Trading’s NovoCure NVCR Stock Holding History

Spot Trading’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-25,000
Closed -$196K – 3206
2016
Q4 		$196K Sell
25,000
-82,500
-77% -$664K ﹤0.01% 1934
2016
Q3 		$918K Buy
107,500
+90,800
+544% +$828K 0.02% 1114
2016
Q2 		$195K Buy
+16,700
New +$209K ﹤0.01% 2244

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

Spot Trading's NVCR Position: Q3 2016 in Review

Spot Trading sold out of NovoCure (NVCR) in Q3 2016, closing a stake of 3,899 shares — an estimated $35.6K sold.

Spot Trading first reported a position in NVCR in Q2 2016 and held it in 1 quarter. The position peaked at $46K in Q2 2016. 63 funds tracked by Wall St. Rank hold NVCR as of Q3 2016.

  • Spot Trading reported no remaining NovoCure position as of Q3 2016 after selling out during the quarter.
  • Spot Trading sold 3,899 NovoCure shares in Q3 2016, an estimated $35.6K.
  • Spot Trading first reported a position in NovoCure in Q2 2016 and held it in 1 quarter.
  • Spot Trading's NovoCure position peaked at $46K in Q2 2016.
  • 63 funds tracked by Wall St. Rank held NovoCure as of Q3 2016.

Based on Spot Trading's 13F filing for Q3 2016, filed 31 Oct 2016.